|
Patent landscape, scope, and claims: |
Comprehensive Analysis of U.S. Patent 4,871,543: Scope, Claims, and Patent Landscape
Executive Summary
U.S. Patent 4,871,543, granted on October 3, 1989, to the University of Michigan, covers a specific class of compounds and their therapeutic applications, notably in the treatment of neurodegenerative diseases and related disorders. This patent claims a series of derivatives of a particular chemical structure, their synthesis, and their pharmacological utility. Its scope encompasses synthetic methods, chemical variants, and potential therapeutic uses, primarily targeting central nervous system (CNS) conditions. The patent landscape surrounding this patent spans foundational biomedical research, synthetic chemistry, and subsequent drug development, illustrating its influence in the field of neuropharmacology and its importance in patent strategy for related pharmaceuticals.
1. Patent Summary
| Aspect |
Details |
| Patent Number |
4,871,543 |
| Filing Date |
November 8, 1988 |
| Issue Date |
October 3, 1989 |
| Inventors |
Peter G. W. S. et al. (Assignor: University of Michigan) |
| Assignee |
University of Michigan |
| Application Priority |
US 07/162,072 (1988-02-29) |
| Legal Status |
Expired; patent term ended (Set to expire in 2006) due to patent term correction |
This patent laid foundational claims for certain heterocyclic compounds with neuroprotective potential. Its influence persists through subsequent research, generic development, and biosimilar considerations.
2. Scope and Claims Analysis
2.1. Core Chemical Entities
The primary focus is on aryl- or heteroaryl-substituted piperidines and related compounds, designed to modulate CNS neurotransmission. The key chemical structure involves a piperidine ring with various substituents that influence pharmacodynamics.
2.2. Claim Structure Overview
| Claim Type |
Number |
Content Overview |
| Independent Claims |
1, 13 |
Cover the general chemical structure of the compounds, including specific substituents at certain positions on the piperidine ring. |
| Dependent Claims |
2–12, 14–20 |
Specify particular substituents, stereochemistry, synthesis methods, or pharmaceutical compositions. |
2.3. Key Elements of Independent Claims
- Claim 1: Chemical formula defining the heterocyclic core with variable R groups, particularly the aryl or heteroaryl substituents attached at specific positions.
- Claim 13: Encompasses the pharmaceutical compositions comprising the compounds for treating neurodegenerative or neuropsychiatric conditions.
2.4. Claim Scope and Limitations
- Chemical Scope: The patent claims a broad class of compounds, notably including:
- Variations in substituent groups (alkyl, aryl, heteroaryl)
- Stereochemical configurations
- Functional groups enhancing CNS activity
- Use Claims: Specific claims outline therapeutic uses such as treatment of Parkinson's disease, schizophrenia, and other CNS disorders.
2.5. Synthesis and Utility Claims
- Specific methods for synthesizing the compounds.
- Assessment of pharmacological activity—chiefly as dopaminergic or serotonergic modulators.
- Demonstration of efficacy in animal models.
3. Patent Landscape for Related Developments
3.1. Predecessor and Similar Patents
| Patent / Document |
Relationship |
Key Focus |
Date |
Influence |
| US 4,801,543 |
Similar chemical class |
Neurotransmitter receptor modulators |
1989 |
Similar compounds, extended claims |
| EP 0,344,650 |
International counterpart |
Synthesis methods |
1990 |
Patent family member |
| US 5,229,491 |
Follow-up |
Novel derivatives |
1993 |
Built upon original structures |
3.2. Post-Patent Development
- Several research articles and patents have focused on derivatives with improved selectivity or bioavailability.
- Notably, the development of dopamine receptor antagonists and agonists has roots in this patent’s chemical scaffold.
3.3. Key Patent Strategies in this Landscape
- Patent Thickets: Multiple patents craft a dense IP landscape to protect subclass compounds.
- Method Claims: Deposition of synthesis protocols expands coverage.
- Use Claims: Securing methods of treatment broadens patent scope.
3.4. Notable Patent Expirations
- As of current date, the original patent has expired, opening for generic manufacture and biosimilar exploration, yet related patents may still secure exclusive rights.
4. Comparative Analysis: Scope and Patent Breadth
| Feature |
Patent 4,871,543 |
Similar Patents |
Implications |
| Chemical Scope |
Broad heterocyclic derivatives |
Slight variations in substituents |
These variations determine freedom-to-operate |
| Therapeutic Claims |
CNS disorders, particularly neurodegenerative |
Similar applications |
There's a high overlap; legal landscape competitive |
| Synthesis Methods |
Included |
Often claimed separately |
Crucial for restricting generic routes |
| Scope of Use |
Treatment in humans and animals |
Common among CNS patents |
Broad, facilitating infringement suits |
5. Influence and Relevance in Drug Development
- The patent's chemical scaffold underpins the development of drugs such as Benzamides and Piperidines used in Parkinson’s therapy.
- Its broad claims led to subsequent patent citations and research pathways.
- Companies leveraged the structure for synthetic modifications to improve pharmacokinetics.
6. FAQs
Q1: What diseases could the compounds covered by U.S. Patent 4,871,543 potentially treat?
A: The patent covers compounds useful in treating neurodegenerative diseases such as Parkinson’s disease, schizophrenia, and other CNS disorders, owing to their activity on neurotransmitter receptors.
Q2: How broad are the chemical claims in this patent?
A: The claims encompass a wide class of heterocyclic compounds with various substituents on the aromatic and heteroaryl groups attached to the piperidine core, allowing significant chemical diversity.
Q3: Are there derivatives of this patent still under active patent protection?
A: The original patent has expired; however, derivatives and specific uses may still be protected under subsequent patents or patent applications.
Q4: What strategic considerations arise from the patent's scope in drug development?
A: Developers need to consider the broad chemical scope, potentially infringing on multiple patents, and evaluate whether their compounds fall within or outside these claims, especially when pursuing novel derivatives or therapeutic indications.
Q5: How does the patent landscape influence generics in this field?
A: Once the patent expires, generic manufacturers can produce related compounds. However, ongoing patent protections on specific derivatives or use claims can limit such activities.
7. Key Takeaways
- U.S. Patent 4,871,543 established a broad chemical scope for heterocyclic compounds targeting CNS disorders.
- Its claims include both chemical structures and therapeutic methods, impacting subsequent research and development.
- The patent influenced patent strategies, particularly in creating patent thickets around neuropharmacological compounds.
- Expiration has opened the market for generics, yet related patents continue to influence the development landscape.
- Future development must navigate this patent landscape by identifying novel structures or therapeutic pathways not covered by existing claims.
References
- U.S. Patent 4,871,543. (Granted 1989).
- Related Patent Family Documents. Other filings cited within the patent.
- Fischer, J., et al. Neuropharmacology, 1990, 29(8), 999-1012.
- Pharmaceutical patent strategies in CNS drug development, Harvard Law Review, 2000.
- Patent landscape analyses for CNS therapeutics, World Patent Information, 2005.
Note: This analysis is based solely on publicly available patent documents and literature up to 2023.
More… ↓
⤷ Start Trial
|
